The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the monthly intravenous (IV) maintenance regimen of Leqembi ® (lecanemab-irmb) for early ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance ... that is specific to the subcutaneous form. In a statement, Eisai and Biogen said ...

The VHA website states that veterans who request lecanemab must be over 65, sign a consent form, have been diagnosed ... VHA will be paying for the drug. Leqembi’s annual list price is $26,500.